Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus
| Autor: | Gholamreza Adeli, Gayane Melikyan, Amir Boshra, Mohamed S. Abdelmoneim, Beatriz Canibano, Boulenouar Mesraoua, Dirk Deleu, Osama Elalamy, Yasir Ali |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Consensus Dimethyl Fumarate 030204 cardiovascular system & hematology Disease activity 03 medical and health sciences 0302 clinical medicine Multiple Sclerosis Relapsing-Remitting medicine Humans In patient 030212 general & internal medicine Intensive care medicine business.industry Multiple sclerosis Natalizumab Expert consensus Patient Preference General Medicine Glatiramer Acetate Interferon-beta medicine.disease Management of multiple sclerosis Relapsing remitting Family Planning Services business Consensus guideline Healthcare system |
| Zdroj: | Current medical research and opinion. 36(2) |
| ISSN: | 1473-4877 |
| Popis: | Healthcare systems vary greatly between countries. International, evidence-based guidelines for the management of multiple sclerosis (MS) may need to be adapted for use in particular countries. Two years ago, the authors published a comprehensive consensus guideline for the management of MS in Qatar. Since that time, the availability of disease-modifying treatments for relapsing-remitting MS (RRMS), and our understanding of how to apply those treatments, has increased. The authors present an update to our guidance, focussing on the management of relapsing-remitting RRMS. In particular, the authors consider the optimal use of different DMTs in patients presenting with mild, medium or high disease activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|